Literature DB >> 34156976

The clear cell sarcoma functional genomic landscape.

Emanuele Panza1,2, Benjamin B Ozenberger3, Krystal M Straessler1,3, Jared J Barrott3, Li Li3, Yanliang Wang3, Mingchao Xie4, Anne Boulet1, Simon Wa Titen1, Clinton C Mason5, Alexander J Lazar6, Li Ding4, Mario R Capecchi1, Kevin B Jones3.   

Abstract

Clear cell sarcoma (CCS) is a deadly malignancy affecting adolescents and young adults. It is characterized by reciprocal translocations resulting in expression of the chimeric EWSR1-ATF1 or EWSR1-CREB1 fusion proteins, driving sarcomagenesis. Besides these characteristics, CCS has remained genomically uncharacterized. Copy number analysis of human CCSs showed frequent amplifications of the MITF locus and chromosomes 7 and 8. Few alterations were shared with Ewing sarcoma or desmoplastic, small round cell tumors, which are other EWSR1-rearranged tumors. Exome sequencing in mouse tumors generated by expression of EWSR1-ATF1 from the Rosa26 locus demonstrated no other repeated pathogenic variants. Additionally, we generated a new CCS mouse by Cre-loxP-induced chromosomal translocation between Ewsr1 and Atf1, resulting in copy number loss of chromosome 6 and chromosome 15 instability, including amplification of a portion syntenic to human chromosome 8, surrounding Myc. Additional experiments in the Rosa26 conditional model demonstrated that Mitf or Myc can contribute to sarcomagenesis. Copy number observations in human tumors and genetic experiments in mice rendered, for the first time to our knowledge, a functional landscape of the CCS genome. These data advance efforts to understand the biology of CCS using innovative models that will eventually allow us to validate preclinical therapies necessary to achieve longer and better survival for young patients with this disease.

Entities:  

Keywords:  Cancer; Genetics; Mouse models; Oncogenes; Oncology

Mesh:

Substances:

Year:  2021        PMID: 34156976      PMCID: PMC8321568          DOI: 10.1172/JCI146301

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  38 in total

1.  A Cre/loxP-deleter transgenic line in mouse strain 129S1/SvImJ.

Authors:  Shih-Huey E Tang; Francisco J Silva; Walter M K Tsark; Jeffrey R Mann
Journal:  Genesis       Date:  2002-03       Impact factor: 2.487

2.  A highly efficient recombineering-based method for generating conditional knockout mutations.

Authors:  Pentao Liu; Nancy A Jenkins; Neal G Copeland
Journal:  Genome Res       Date:  2003-03       Impact factor: 9.043

3.  Molecular basis of mouse microphthalmia (mi) mutations helps explain their developmental and phenotypic consequences.

Authors:  E Steingrímsson; K J Moore; M L Lamoreux; A R Ferré-D'Amaré; S K Burley; D C Zimring; L C Skow; C A Hodgkinson; H Arnheiter; N G Copeland
Journal:  Nat Genet       Date:  1994-11       Impact factor: 38.330

4.  Chromosome instability accounts for reverse metastatic outcomes of pediatric and adult synovial sarcomas.

Authors:  Pauline Lagarde; Joanna Przybyl; Céline Brulard; Gaëlle Pérot; Gaelle Pierron; Olivier Delattre; Raf Sciot; Agnieszka Wozniak; Patrick Schöffski; Philippe Terrier; Agnès Neuville; Jean-Michel Coindre; Antoine Italiano; Daniel Orbach; Maria Debiec-Rychter; Frédéric Chibon
Journal:  J Clin Oncol       Date:  2013-01-14       Impact factor: 44.544

5.  Molecular inversion probe analysis detects novel copy number alterations in Ewing sarcoma.

Authors:  Mona S Jahromi; Angelica R Putnam; Colleen Druzgal; Jennifer Wright; Holly Spraker-Perlman; Michelle Kinsey; Holly Zhou; Kenneth M Boucher; R Lor Randall; Kevin B Jones; David Lucas; Andrew Rosenberg; Dafydd Thomas; Stephen L Lessnick; Joshua D Schiffman
Journal:  Cancer Genet       Date:  2012 Jul-Aug

6.  In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system.

Authors:  Danilo Maddalo; Eusebio Manchado; Carla P Concepcion; Ciro Bonetti; Joana A Vidigal; Yoon-Chi Han; Paul Ogrodowski; Alessandra Crippa; Natasha Rekhtman; Elisa de Stanchina; Scott W Lowe; Andrea Ventura
Journal:  Nature       Date:  2014-10-22       Impact factor: 49.962

7.  Cell-type dependent enhancer binding of the EWS/ATF1 fusion gene in clear cell sarcomas.

Authors:  Shingo Komura; Kenji Ito; Sho Ohta; Tomoyo Ukai; Mio Kabata; Fumiaki Itakura; Katsunori Semi; Yutaka Matsuda; Kyoichi Hashimoto; Hirofumi Shibata; Masamitsu Sone; Norihide Jo; Kazuya Sekiguchi; Takatoshi Ohno; Haruhiko Akiyama; Katsuji Shimizu; Knut Woltjen; Manabu Ozawa; Junya Toguchida; Takuya Yamamoto; Yasuhiro Yamada
Journal:  Nat Commun       Date:  2019-09-05       Impact factor: 14.919

8.  The impact of chromosomal translocation locus and fusion oncogene coding sequence in synovial sarcomagenesis.

Authors:  K B Jones; J J Barrott; M Xie; M Haldar; H Jin; J-F Zhu; M J Monument; T L Mosbruger; E M Langer; R L Randall; R K Wilson; B R Cairns; L Ding; M R Capecchi
Journal:  Oncogene       Date:  2016-03-07       Impact factor: 9.867

9.  Recurrent secondary genomic alterations in desmoplastic small round cell tumors.

Authors:  Warren A Chow; Jiing-Kuan Yee; Walter Tsark; Xiwei Wu; Hanjun Qin; Min Guan; Jeffrey S Ross; Siraj M Ali; Sherri Z Millis
Journal:  BMC Med Genet       Date:  2020-05-11       Impact factor: 2.103

10.  Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas.

Authors: 
Journal:  Cell       Date:  2017-11-02       Impact factor: 41.582

View more
  1 in total

1.  Comprehensive genomic profiling of EWSR1/FUS::CREB translocation-associated tumors uncovers prognostically significant recurrent genetic alterations and methylation-transcriptional correlates.

Authors:  Josephine K Dermawan; Fabio Vanoli; Laurie Herviou; Yun-Shao Sung; Lei Zhang; Samuel Singer; William D Tap; Ryma Benayed; Tejus A Bale; Jamal K Benhamida; Brendan C Dickson; Cristina R Antonescu
Journal:  Mod Pathol       Date:  2022-03-28       Impact factor: 8.209

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.